Sequencing continues to have the potential to transform clinical microbiology and even public health by enabling the simultaneous, hypothesis-free identification of multiple disease-causing organisms (including bacteria, viruses, fungi and parasites). Multiple approaches for this type of testing exist – from sampling of microbes in sources of infection to newer cell-free approaches from body fluids. Despite its tremendous promise, sequencing has not seen the routine uptake many predicted due to a variety of technical, scientific and broader structural reasons.
While implementation in routine practice remains in early stages, the potential impact on healthcare delivery and patient outcomes warrants serious consideration from forward-looking healthcare leaders.
Join us for a dynamic moderated discussion between two widely recognized experts in the field of microbiology, Charles Chiu, MD PhD, and Brad Perkins, MD, as they discuss the future of sequencing in clinical microbiology.
Discussion Highlights:
- Sequencing’s transformative potential in diagnostics.
- Real-world patient impact and success stories.
- Assessing where we are in the adoption cycle.
- Advances in various types of methodologies, infrastructure, and approaches.
- Addressing unmet needs in infectious disease diagnostics and healthcare delivery.
- Building the clinical evidence base to drive broader adoption.
- Overcoming barriers through innovation, collaboration, and guideline development.
- Envisioning the future.
